Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK initially offered the HIV therapy for free but withdrew from the clinical trial in Africa after investigators revised one of three study arms, setting up a comparative effectiveness trial, Waxman says. GSK will now offer the drug at a "nonprofit," "developing country" price of 65¢ per day.

You may also be interested in...

Abbott Norvir Compulsory Licensing Would Take Several Years, NIH Says

NIH cannot grant Norvir patent licenses under the Bayh/Dole Act until Abbott has exhausted its appeals process, and follow-on products would have to gain standard FDA approval, the agency says. NIH expects to make a decision on whether to apply its "march-in" authority for the HIV product as soon as possible. The precedent established could have an immediate effect; NIH received a petition requesting the use of march-in rights for Pfizer's Xalatan.

“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says

Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.

PBMs Object To Real-Time Prior Authorization As Part Of E-Prescribing

Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts